Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-19-364

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)

Closed on January 10, 2022.

Posted
September 3, 2019
Close date
January 10, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $223,850 in first-year total cost, median $223,850.

Most frequent study sections

  1. HIV Coinfections and HIV Associated Cancers Study Section[HCAC]1

Most frequent institutions

  1. TUFTS UNIVERSITY BOSTON1
Competing awards under PAR-19-364 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Myeloid-Derived Suppressor Cells in Tuberculosis Granuloma Structure and Function1R21AI155003-01MARTINOT, AMANDATUFTS UNIVERSITY BOSTON, MA$223,850HCAC

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-19-364: Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience